Gentian Diagnostics AS - Asset Resilience Ratio
Gentian Diagnostics AS (GENT) has an Asset Resilience Ratio of 40.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gentian Diagnostics AS (GENT) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Gentian Diagnostics AS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GENT asset base.
Liquid Assets Composition Over Time
This chart breaks down Gentian Diagnostics AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read GENT liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr105.93 Million | 40.97% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr105.93 Million | 40.97% |
Asset Resilience Insights
- Very High Liquidity: Gentian Diagnostics AS maintains exceptional liquid asset reserves at 40.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gentian Diagnostics AS Industry Peers by Asset Resilience Ratio
Compare Gentian Diagnostics AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A
SHE:300760 |
Medical Devices | 0.64% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Brainsway Ltd
NASDAQ:BWAY |
Medical Devices | 0.87% |
|
Tactile Systems Technology Inc
NASDAQ:TCMD |
Medical Devices | 5.59% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
Annual Asset Resilience Ratio for Gentian Diagnostics AS (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Gentian Diagnostics AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.90% | Nkr84.74 Million ≈ $8.92 Million |
Nkr229.66 Million ≈ $24.17 Million |
+35.79pp |
| 2023-12-31 | 1.11% | Nkr2.01 Million ≈ $211.62K |
Nkr181.04 Million ≈ $19.05 Million |
+0.01pp |
| 2022-12-31 | 1.11% | Nkr2.08 Million ≈ $218.46K |
Nkr187.79 Million ≈ $19.76 Million |
-53.16pp |
| 2021-12-31 | 54.27% | Nkr114.94 Million ≈ $12.09 Million |
Nkr211.79 Million ≈ $22.29 Million |
-12.88pp |
| 2020-12-31 | 67.15% | Nkr157.99 Million ≈ $16.62 Million |
Nkr235.26 Million ≈ $24.76 Million |
-8.22pp |
| 2019-12-31 | 75.37% | Nkr171.24 Million ≈ $18.02 Million |
Nkr227.18 Million ≈ $23.91 Million |
-1.49pp |
| 2018-12-31 | 76.87% | Nkr198.31 Million ≈ $20.87 Million |
Nkr257.98 Million ≈ $27.15 Million |
+6.21pp |
| 2017-12-31 | 70.65% | Nkr145.00 Million ≈ $15.26 Million |
Nkr205.23 Million ≈ $21.60 Million |
+10.40pp |
| 2016-12-31 | 60.25% | Nkr74.09 Million ≈ $7.80 Million |
Nkr122.96 Million ≈ $12.94 Million |
-- |
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more